BG62870B2 - Метод за получаване на човешка дезоксирибонуклеаза - Google Patents

Метод за получаване на човешка дезоксирибонуклеаза Download PDF

Info

Publication number
BG62870B2
BG62870B2 BG098613A BG9861394A BG62870B2 BG 62870 B2 BG62870 B2 BG 62870B2 BG 098613 A BG098613 A BG 098613A BG 9861394 A BG9861394 A BG 9861394A BG 62870 B2 BG62870 B2 BG 62870B2
Authority
BG
Bulgaria
Prior art keywords
dnaase
polypeptide
human
amino acid
dna
Prior art date
Application number
BG098613A
Other languages
Bulgarian (bg)
English (en)
Inventor
Steven Shak
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26965935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62870(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BG62870B2 publication Critical patent/BG62870B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
BG098613A 1988-12-23 1994-02-28 Метод за получаване на човешка дезоксирибонуклеаза BG62870B2 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28995888A 1988-12-23 1988-12-23
US44803889A 1989-12-08 1989-12-08

Publications (1)

Publication Number Publication Date
BG62870B2 true BG62870B2 (bg) 2000-09-29

Family

ID=26965935

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098613A BG62870B2 (bg) 1988-12-23 1994-02-28 Метод за получаване на човешка дезоксирибонуклеаза

Country Status (11)

Country Link
US (3) US20030044403A1 (fr)
EP (2) EP0449968B1 (fr)
JP (2) JP3162372B2 (fr)
AT (2) ATE176924T1 (fr)
AU (1) AU630658B2 (fr)
BG (1) BG62870B2 (fr)
CA (1) CA2006473C (fr)
DE (2) DE68929551T2 (fr)
ES (1) ES2130120T3 (fr)
HU (1) HU211232A9 (fr)
WO (1) WO1990007572A1 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929551T2 (de) * 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
EP0748225B1 (fr) * 1994-03-04 2004-06-09 Genentech, Inc. FORMULATION DE DNase PHARMACEUTIQUEMENT ACCEPTABLE
WO1995023854A1 (fr) * 1994-03-04 1995-09-08 Genentech, Inc. AMELIORATION DES SOLUTIONS LIQUIDES D'ADN-ase
WO1995030428A1 (fr) * 1994-05-05 1995-11-16 Human Genome Sciences, Inc. Deoxyribonuclease chez l'homme
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5821103A (en) * 1994-09-06 1998-10-13 Tanuma; Sei-Ichi Deoxyribonuclease
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
CA2210871C (fr) * 1995-02-24 2009-04-07 Genentech, Inc. Variantes de la dnase i humaine
CZ297463B6 (cs) * 1995-02-24 2006-12-13 Genentech, Inc. Varianta lidské DNázy I, mající DNA hydrolytickouaktivitu a aminokyselinovou sekvenci mající nejméne 90 % identity s aminokyselinovou sekvencí prírodní lidské DNázy I
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
DE19521046C1 (de) * 1995-06-09 1996-08-08 Deutsches Krebsforsch Protein mit DNase-Aktivität
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
AU727310B2 (en) * 1996-02-05 2000-12-07 Genentech Inc. Human DNASE resistant to actin inhibition
US6265195B1 (en) * 1996-04-25 2001-07-24 Genentech, Inc. Human DNase II
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
WO2001012793A1 (fr) 1999-08-17 2001-02-22 Tanuma Sei Ichi Nouvelle desoxyribonuclease, gene codant cette derniere, et procede de production de cette derniere
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CN102180944A (zh) 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7118901B2 (en) 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
EP1433842B1 (fr) * 2002-12-18 2011-01-05 Roche Diagnostics GmbH Désoxyribonucléase I recombinante issue de pancréas bovine à haute activité spécifique
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
JP4542090B2 (ja) 2003-04-09 2010-09-08 ネクター セラピューティクス カプセル穿刺整合ガイドを有するエアロゾル化装置
EP1613261A4 (fr) 2003-04-09 2011-01-26 Novo Nordisk As Formation intracellulaire de conjugues de peptides
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7405198B2 (en) 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
WO2005111225A1 (fr) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag Glycoformes de polypeptides o-liees et leur procede de fabrication
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (fr) 2004-09-10 2007-06-27 Neose Technologies, Inc. Interferon alpha glycopegyle
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
EP2386571B1 (fr) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
EP1880733A4 (fr) * 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Procede pour prolonger la duree de vie d'animaux ou de l'humain
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2049144B8 (fr) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
AU2007311444B2 (en) * 2006-10-18 2012-11-29 Periness Ltd. Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
ES2369547T3 (es) * 2006-11-28 2011-12-01 Cls Therapeutics Limited Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
WO2012106264A2 (fr) * 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Traitement et prévention d'une vaginose bactérienne et d'infections par gardnerella vaginalis
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
US20160030527A1 (en) * 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Compositions and Methods for Treatment of Stroke
US10988745B2 (en) * 2013-10-31 2021-04-27 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
EP3214172B1 (fr) 2014-10-31 2019-02-13 JCR Pharmaceuticals CO., LTD. Procédé pour la production de dnase i humaine recombinée
EP3240896A1 (fr) * 2015-01-04 2017-11-08 Protalix Ltd. Dnase modifiée et ses utilisations
EP3797789B1 (fr) 2015-01-20 2024-08-21 The Children's Medical Center Corporation Composés anti-net pour traiter ou prévenir la fibrose et pour faciliter la cicatrisation des plaies
JP6745873B2 (ja) 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン，ドミトリー 神経変性における治療標的としての細胞外ｄｎａ
DE102015118011A1 (de) * 2015-10-22 2017-04-27 Human Med Ag Vorrichtung zur Transplantation von Körperfett
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MX2019005617A (es) 2016-11-17 2019-08-14 Iovance Biotherapeutics Inc Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
EP3351263A1 (fr) * 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Composition pharmaceutique destinée au traitement ou à la prévention de l'adhérence tissulaire
WO2019143272A1 (fr) * 2018-01-16 2019-07-25 Cls Therapeutics Limited Traitement de maladies par expression hépatique d'une enzyme qui a une activité désoxyribonucléase (dnase)
WO2022074656A1 (fr) 2020-10-07 2022-04-14 Protalix Ltd. Dnase à action prolongée
US11993792B2 (en) 2021-05-27 2024-05-28 New England Biolabs, Inc. DNase I variants, compositions, methods, and kits

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (fr) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation et purification de la desoxyribonuclease
JPS55131389A (en) * 1979-04-02 1980-10-13 Amano Pharmaceut Co Ltd Purification of deoxyribonuclease i
DE68929551T2 (de) * 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US6251648B1 (en) * 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase

Also Published As

Publication number Publication date
JPH04502406A (ja) 1992-05-07
EP0853121A3 (fr) 1998-08-05
DE68929551T2 (de) 2008-03-06
HU211232A9 (en) 1995-11-28
ATE358176T1 (de) 2007-04-15
US7297526B2 (en) 2007-11-20
DE68928934T2 (de) 1999-08-05
CA2006473C (fr) 2002-02-05
DE68929551D1 (de) 2007-05-10
CA2006473A1 (fr) 1990-06-23
JP2001157580A (ja) 2001-06-12
US20080026426A1 (en) 2008-01-31
US20050009056A1 (en) 2005-01-13
EP0449968A1 (fr) 1991-10-09
DE68928934D1 (de) 1999-04-01
AU630658B2 (en) 1992-11-05
ES2130120T3 (es) 1999-07-01
EP0853121A2 (fr) 1998-07-15
EP0449968B1 (fr) 1999-02-24
WO1990007572A1 (fr) 1990-07-12
EP0853121B1 (fr) 2007-03-28
JP3162372B2 (ja) 2001-04-25
US20030044403A1 (en) 2003-03-06
ATE176924T1 (de) 1999-03-15
AU4826590A (en) 1990-08-01

Similar Documents

Publication Publication Date Title
BG62870B2 (bg) Метод за получаване на човешка дезоксирибонуклеаза
KR100547402B1 (ko) α-갈락토시다아제 Ａ 결핍을 치료하는 방법
US6083725A (en) Tranfected human cells expressing human α-galactosidase A protein
US20080058256A1 (en) Methods for the treatment of thrombosis
JPH03505527A (ja) 精製されたユビキチン・ヒドロラーゼ、それをコードするｄｎａ配列、およびポリペプチド回収の際のその使用
JP3469247B2 (ja) 組換えリボヌクレアーゼタンパク質
EP0437427A1 (fr) Dimeres clives de polypeptides semblables a substance d'inhibition mullerienne
CA1341459C (fr) Enzymes fibrinolytiques modifiees
EP0542869B1 (fr) Variants d'activateur de plasminogene tissulaire avec espacement reduit
AU2003220717B2 (en) Therapy for alpha-galactosidase a deficiency
AU2012227349B2 (en) Therapy for alpha-galactosidase A deficiency
JPH09503646A (ja) アンチトロンビンポリペプチド類似体及びその製造法
JPH06502544A (ja) 組織プラスミノーゲン活性化因子置換変異体